AstraZeneca Pharmaceutical's Tagrisso was approved by the Food and Drug Administration (FDA) Nov. 13 as a treatment for advanced non-small cell lung cancer (NSCLC). Read More »

The Food and Drug Administration (FDA) approved the first nasal spray version of naloxone Wednesday as an emergency life-saving treatment for opioid overdose. Read More »

American Society of Health-System Pharmacists honoring those who have made biomed literature contributions. Read More »

Genentech's drug Cotellic was approved by the U.S. Food and Drug Administration (FDA) this week as a combination treatment for advanced melanoma. Read More »

The Pharmacy Practice Model Initiative has been renamed Practice Advancement Initiative (PAI), according to an announcement from the American Society of Health-System Pharmacists (ASHP) Foundation and the ASHP. Read More »

AstraZeneca has entered into a deal to acquire ZS Pharma for $2.7 billion, giving AstraZeneca access to ZS Pharma's treatments for hyperkalemia. Read More »

Clinical studies showed that Nucala was effective in reducing exacerbations that would require hospitalization. Read More »

New Haven Pharmaceuticals said data on the antiplatelet effects of Durlaza will be presented in a poster session during the American Heart Association Scientific Sessions that begin this weekend in Orlando, Florida. Read More »

The FDA has granted priority review of Acadia Pharmaceuticals' new drug application (NDA) for Nuplazid (pimavanserin) that is intended to treat Parkinson's disease psychosis. Read More »

The American Society of Health-System Pharmacists (ASHP) said legislation pending in the U.S. House of Representatives that would help the medically underserved needs four more co-sponsors to get to the next phase. Read More »

The U.S. Food and Drug Administration approved Strensiq (asfotase alfa) to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP), a rare, genetic, progressive, metabolic disease. Read More »

The U.S. Food and Drug Administration (FDA) recently approved Veltassa (patiromer for oral suspension) to treat patients with elevated levels of potassium in the blood, a condition known as hyperkalemia. Read More »

Track and Trace requirements scheduled to go into effect Sunday have been delayed until March 1, according to a Thursday announcement from the Food and Drug Administration (FDA). Read More »

Imlygic (talimogene laherparepvec) has become the first FDA-approved oncolytic virus therapy indicated for the treatment of melanoma lesions in the skin and lymph nodes. Read More »

The American Society of Health-System Pharmacists (ASHP) recently published its annual compilation, ASHP Best Practices, featuring information such as quality policy positions, statements, guidelines, therapeutic position statements, and therapeutic and clinical practice guidelines for the pharmacy profession. Read More »

ClearPath Development Co. has partnered with Astellas Pharma Inc. to form a second vaccine company, Nosocomial Vaccine Corp. (NVC). Read More »

The Food and Drug Administration (FDA) has expanded the approved uses of Yervoy (ipilimumab) to treat patients with Stage III melanoma. Read More »

The Food and Drug Administration (FDA) has approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, for patients with advanced pancreatic cancer who have been treated previously with gemcitabine-based chemotherapy. Read More »

The American Society of Health-System Pharmacists (ASHP) said Thursday it will hold its first virtual House of Delegates session Nov. 13-20 to give delegates the chance to take early action on ASHP policy recommendations through online discussion and voting. Read More »

The U.S. Food and Drug Administration (FDA) recently approved Dyanavel XR (amphetamine), extended-release oral suspension, CII, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children six years and older, according to an announcement from Tris Pharma Inc. on Tuesday. Read More »